Click Here to Register »

Executive Sponsors

Cambridge Consultants

Associate Sponsors


Technology Sponsors

Caisson Biotech
Credence MedSystems
Delta Mod Tech
Enable Injections
Glide Technologies
Insulet Corporation
Oval Medical
PKA SoftTouch
Salvona Technologies
Sensile Medical
Terumo Medical

Supporting Sponsor

Team Consulting


Baumann Group
Beuhler Motor
Stress Engineering

Soapbox Sponsors

Cyta Therapeutics
Portal Instruments
Suono Bio

Media Partners

On Drug Delivery
Can Biotech
Current Partnering
Drug Development & Delivery
Massachusetts Life Sciences Center
MCD Group
Med Device Online
Medical News Today


  • 8:00 am

  • Breakfast & Registration

    Hosted by:


  • 8:45 am

  • Chair’s Opening Remarks

    Chair’s Opening Remarks

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 9:00 am

  • Opening Keynote Address on Nanotechnology

    Opening Keynote Address on Nanotechnology

    Robert Langer, PhD
    David H. Koch Institute Professor, MIT

  • 9:50 am

  • Keynote: Enabling Patient Centric Therapies through Innovation in Personalized Healthcare and Drug Delivery

    We are delighted to welcome our 2015 industry keynote, Dr Bahija Jallal, EVP, MedImmune. Dr Jallal is responsible for biologics research, development and clinical activities. As part of AstraZeneca’s Senior Executive Team, she is tasked with advancing the biologic organization’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders and pain. Joining Dr Jallal on the stage is PODD veteran, Dr Anand Subramony, VP, Drug Delivery & Device Development, MedImmune. Together, they will speak on the following:

    Drug delivery and connected health technologies will deliver patient centric therapeutics and will transform how patients manage their health in the near future. As personalized health care strategies and companion diagnostics become reality, pharmaceutical and biotech companies are shifting to a “patient outcome”, or ‘pay for value’ based model. Pharma models are therefore evolving toward creating total solutions for patients rather than simply acting as a provider of dosage forms. Drug delivery plays an important role in this new paradigm. The emergence of biologics have led to the development of novel devices for parenteral delivery and has redefined the need for novel drug delivery technologies for biologics.

    Bahija Jallal, PhD
    EVP, AstraZeneca, Head of MedImmune


    Anand Subramony, PhD
    VP, Drug Delivery & Device Development, MedImmune

  • 10:30 am

  • Networking Break & Partnering Meetings

  • 11:15 am

  • Licensing Drug Delivery Technologies for Oncology Therapeutics

    In this panel, we will hear from business development and licensing executives regarding current level of interest in drug delivery technologies for pipeline and launched drugs.

    • Licensing improved formulations of off-patent cancer drugs vs. enabling platform technologies for NCEs
    • Criteria used to evaluate novel oncology drug delivery systems
    • What stage and type of data is most attractive to pharmaceutical partners?
    • Types of formulations and technology platforms actively sought:
      • Nanotechnology-based/Nanomedicine
      • Antibody drug conjugates
      • Sustained release depots/implants
    • Structuring partnerships – platform vs. product licenses, option-based agreements, regional deals

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

    PJ Anand
    Founder, President & CEO, Alcyone Lifesciences Inc.

    Vahe Bedian, PhD
    Director, Oncology External Projects, AstraZeneca

    Yalia Jayalakshmi (Jaya), PhD
    Senior Director, Drug Delivery Technologies, Onyx Pharmaceutical

    Philippe Lopes-Fernandes
    SVP, Head of Global Licensing & Business Development, Merck Serono / EMD Serono

    Denis Patrick, PhD
    Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer

  • 12:00 pm

  • The SoloStar Injection Device: Foundation for a Versatile Platform

    Paul Jansen
    VP, Medical Device Development, Sanofi

    Rob Veasey
    Senior Sector Manager, Medical and Scientific, DCA Design International

    Bill Welch
    Chief Technology Officer, Phillips-Medisize Corporation

  • 12:40 pm

  • A Year in Review in Drug Delivery: A PharmaCircle Perspective

    Tugrul Kararli, PhD, MBA
    President and Founder, PharmaCircle

  • 12:55 pm

  • Luncheon & Partnering Meetings

  • 2:15 pm

  • Drug Delivery Presentations in Three Tracks

    Track OneNon-Injectable Formulation and Device Technologies
    Chaired by:
    Fernando Sallés, PhD
    VP, Head of Global Search, Teva Pharmaceuticals

    Altus Formulation, Lucideon, Medpharm, Nanologica, Salvona, Tergus Pharma, Vectura, ViSci


    Track TwoInjectable Formulation Technologies
    Chaired by:
    Matthew Burke, PhD
    Head of Drug Delivery, Global Formulations, RD Platform Technology & Science, GSK

    Althea, Bioasis, BioPact, Caisson Biotech, Ceramisphere, Enable, Genisphere, Innocore, Novozymes, Sensile, Starpharma


    Track ThreeDevice Technologies
    Chaired by:
    Tomas Landh MSc, PhD
    VP, Innovation Sourcing, Novo Nordisk

    3M, Balda, Biocorp, Credence, Delta, Glide Technologies, Insulet,Mercator Systems, Mod Tech, Nemera, Oval Medical, PKA SoftTouch, Sonscene, Terumo Medical, Unilife


    There will be a 15-minute break at 4:00 pm.

    If you are interested in presenting in one of the tracks, please contact Meredith Sands at

  • 6:00 pm

  • Cocktail Reception


  • 8:00 am

  • Breakfast & Partnering Meetings

    Hosted by:


  • 8:30 am

  • Chair’s Welcome

    Chair’s Welcome

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 8:45 am

  • How We Built Moderna

    Stéphane Bancel joined Moderna in 2011 when it had one employee and patent and has assembled a company pioneering in the development of messenger RNA (mRNA) Therapeutics. It was recently named the #1 Disruptor on the third-annual CNBC Disruptor 50 list. For the second year in a row, CNBC recognizes Moderna as one of the country’s most ambitious and innovative companies changing the economy and overall business landscape.

    Stéphane Bancel
    CEO, Moderna Therapeutics

  • 9:30 am

  • Utilizing Nanotechnology to Advance Targeted Therapies and Personalized Medicine

    Omid Farokhzad, MD
    Associate Professor, Harvard Medical School

    Werner Cautreels, PhD
    President and CEO, Selecta Biosciences

    Michael Cima, PhD
    David H. Koch Professor of Engineering, MIT

    Drew Fromkin
    President and CEO, Blend Therapeutics

  • 10:15 am

  • Networking Break & Partnering Meetings

  • 11:00 am

  • Technology Spotlight

    Sponsored by:
    3M Drug Delivery Systems

  • 11:20 am

  • Large Volume Drug Delivery – Are Patch Pumps the Answer?

    Due to the increasing need for improved parenteral delivery of high dose pharmaceuticals, especially biologics, a number of new wearable devices have been developed, such as patch pumps and bolus injectors. These devices enable self-administration and eliminate the need for multiple injections or infusions. This panel will discuss the current generation of wearable injection devices and the opportunities and challenges that lie ahead.

    • Key drawbacks of current devices – what should next generation devices address?
    • Beyond insulin, will patch pumps be cost-effective for other drugs such as mAbs?
    • How does the size of the device affect patient acceptability?
    • Implementing acceptance of wearable technology
    • Selecting the appropriate device, and device manufacturer-partner

    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation, Amgen

    Michael Graffeo
    VP, Business Development, Drug Delivery, Insulet Corporation

    David Haase
    Senior Manager, Device Development, Genentech

    Michael Hooven
    President and CEO, Enable Injections

    Iain Simpson
    Associate Director, Drug Delivery, Cambridge Consultants

    Anand Subramony
    VP, Drug Delivery & Device Development, MedImmune

  • 12:00 pm

  • Fifth Annual Company Spotlights

    In this session, we highlight three companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation

    Sanofi-Genzyme BioVentures
    Ann DeWitt, PhD
    Senior Director of Investments

    Abla Creasey, PhD
    Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences

    Eli Lilly
    Divakar Ramakrishnan, PhD
    VP, Drug Delivery/Device R&D and Strategy

  • 1:00 pm

  • Luncheon, Roundtables and Partnering Meetings

    The PODD Luncheon Roundtables are open to all delegates and feature a dedicated moderator with expertise in a particular area. The PODD Roundtables are an excellent way to engage in in-depth discussions and meet colleagues with similar interests. Grab your lunch and choose to join an optional round table or attend partnering meetings.

    Sponsored by:

    Biogen Logo

    Brain Delivery of Large Molecules
    Kapil Gupta, PhD
    Principal Scientist and Group Leader, Protein Pharmaceutical and Device Development, Biogen

    Delivery Strategies for Orphan CNS Diseases
    PJ Anand
    Founder, President and CEO, Alcyone Lifesciences

    Special Considerations in Topical Formulation for Proteins and Peptides
    Vijendra Nalamothu, PhD
    Co-Founder and CEO, Tergus Pharma

    Oral Peptide Delivery
    Andrew Lewis, PhD
    Director Novel Drug Delivery Technologies, CMC & E Peptides, Ipsen

    How to Mitigate Recrystallization: Is Nanotechnology Ready to Offer Real Solutions?
    Andreas Bhagwani
    CEO, Nanologica

  • 2:00 pm

  • Can RNA-based Therapeutics Really Deliver?

    Despite the therapeutic promise of RNA therapeutics, efficient and safe drug delivery remains a significant challenge. These therapeutics tend to have unfavorable physicochemical properties including negative charges, large molecular weight and size, and instability. A number of carrier systems are being developed for RNA therapeutics, including polymers, lipids, and conjugates, but selection of the delivery system depends on the therapeutics properties, type of target cells and the desired delivery route. This panel will discuss:

    • Key hurdles related to delivery of RNA therapeutics: siRNA, mRNA, RNAi
    • Delivery strategies and examples of recent successes
    • Collaborative approaches/models that are working
    • Commercialization prospects given low success rate of RNA drugs to-date

    Jessica Ballinger
    Senior Director, Protein Pharmaceutical Development, Biogen Idec

    Bob Brown, PhD
    CSO, SVP Research, Dicerna Pharmaceuticals

    Abla Creasey
    Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences, Janssen

    Jörg Kaufmann, PhD
    Chief Scientific Officer, Silence Therapeutics

    Muthiah (Mano) Manoharan, PhD
    Senior VP, Drug Discovery, Alnylam Pharmaceuticals

    Dave Rozema
    VP, Chemistry, Arrowhead Research

  • 2:45 pm

  • DDS Technology Soapbox@PODD sponsored by Pfizer

    This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    If you are interested in presenting on the Soapbox, please contact Meredith Sands at

  • 3:45 pm

  • Improving Drug Delivery to the Back of the Eye

    There is an increasing need to successfully treat posterior eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy. Drug delivery to the back of the eye is challenging not only because of the anatomy of the eye and associated static and dynamic barriers, but also due to the growth of biologic therapeutics, and the challenges of delivering and stabilizing these more complex, large molecules. This panel will discuss goals and challenges of delivery, types of delivery systems showing promise for more effective delivery, and the benefits of collaborating in this space.

    James Cunningham, PhD
    Director, Ocular Drug Delivery, Allergan

    Ann Daugherty, PhD
    Senior Manager, Drug Delivery, Genentech

    Justin Hanes, PhD
    Lewis J. Ort Professor, Director, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

    Viral Kansara, PhD
    Investigator and Lab Head – Ocular Pharmacology and Drug Delivery, Novartis

    Jaymin Shah, PhD
    Research Fellow, Pfizer

    Stephen Yoo, MD
    Chief Medical Officer, Regenxbio